NovoCure Limited (NVCR)
NASDAQ: NVCR · IEX Real-Time Price · USD
12.09
+0.04 (0.33%)
At close: Apr 19, 2024, 4:00 PM
12.19
+0.10 (0.83%)
After-hours: Apr 19, 2024, 6:47 PM EDT
NovoCure Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for NovoCure stock have an average target of 45.89, with a low estimate of 15 and a high estimate of 95. The average target predicts an increase of 279.57% from the current stock price of 12.09.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NovoCure stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 3 | 2 | 4 | 4 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $25 → $28 | Buy | Reiterates | $25 → $28 | +131.60% | Apr 10, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $49 → $42 | Buy | Maintains | $49 → $42 | +247.39% | Apr 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $22 → $24 | Hold | Maintains | $22 → $24 | +98.51% | Mar 27, 2024 |
| JP Morgan | JP Morgan | Hold Maintains $15 → $17 | Hold | Maintains | $15 → $17 | +40.61% | Mar 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $22 | Hold | Reiterates | $22 | +81.97% | Mar 12, 2024 |
Financial Forecast
Revenue This Year
549.06M
from 509.34M
Increased by 7.80%
Revenue Next Year
592.27M
from 549.06M
Increased by 7.87%
EPS This Year
-1.79
from -1.95
EPS Next Year
-1.87
from -1.79
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 574.3M | 626.8M | 752.9M | 799.7M | 988.6M |
| Avg | 549.1M | 592.3M | 669.1M | 718.6M | 844.5M |
| Low | 518.4M | 555.7M | 587.0M | 634.5M | 700.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 12.7% | 14.1% | 27.1% | 19.5% | 37.6% |
| Avg | 7.8% | 7.9% | 13.0% | 7.4% | 17.5% |
| Low | 1.8% | 1.2% | -0.9% | -5.2% | -2.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.56 | -1.55 | -1.50 | -1.89 | -1.08 |
| Avg | -1.79 | -1.87 | -1.87 | -1.92 | -1.34 |
| Low | -1.95 | -2.21 | -2.35 | -1.93 | -1.57 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.